Merck withdrew Vioxx in 2004 after evidence of elevated cardiovascular risk; NEJM expressions of concern, FDA reviews, and massive litigation form the paper trail.
On 30 September 2004, Merck announced a worldwide withdrawal of Vioxx (rofecoxib). The COX-2 painkiller had been a blockbuster. It left amid data showing elevated cardiovascular risk and a scientific fight over how clearly earlier trials had spoken.
The APPROVe trial's cardiovascular signal helped force the withdrawal decision. Earlier, the VIGOR study had already raised questions; later New England Journal of Medicine expressions of concern about data presentation became part of the scandal's scholarly spine. This is not blog archaeology. It is clinical-trial culture under fluorescent lights.
Patients who had trusted the brand faced a retrospective roulette of risk. Physicians faced a trust burn. Regulators faced hearings about whether pharmacovigilance had moved fast enough.
Lawsuits by the tens of thousands produced discovery, depositions, and settlements that function as a parallel archive to FDA dockets. Marketing narratives that minimized risk collided with internal documents in courtrooms. Exact legal outcomes varied; the public fact of withdrawal and the scientific dispute over CV risk did not.
Purdue's opioid story is addiction marketing. Thalidomide is teratogenic catastrophe. Vioxx is cardiovascular risk contested through trial design and disclosure. Grouping them teaches pharma-political economy. Merging them into one "they poison everyone" blob teaches nothing actionable.
Dr. Mary's Monkey elsewhere is a different mid-century biomedical underground. Keep it linked loosely as medical-power skepticism, not as Vioxx's prequel.
Vioxx was withdrawn over CV risk evidence. Journals, FDA, and courts argued the timeline of knowledge. Fringe claims that every NSAID is a secret bioweapon are not this file. This file is a named drug, a date of withdrawal, and a mountain of trial paper.
Vioxx's withdrawal dragged attention onto an entire class of COX-2 inhibitors and NSAID risk framing. Class effects debates continue in cardiology. The Archive entry stays with rofecoxib's documentary peak: withdrawal date, trial names, journal concern, litigation volume.
No evidence has been added yet
Purdue Pharma's marketing of OxyContin minimized addiction risk and helped drive the opioid crisis; DOJ settlements, state litigation, and bankruptcy filings created an extensive public record of corporate deception.
A top-secret underground lab in New Orleans accidentally mutated a monkey virus while trying to develop a cancer vaccine, resulting in a highly aggressive, airborne cancer-causing virus that may have entered millions of polio vaccines.
Investigative reporting and academic analyses show Exxon scientists modeled climate risks with notable accuracy even as company public messaging sowed doubt; the gap now fuels fraud litigation and historiography of climate denial.
Sugar Research Foundation Project 226 funded the 1967 McGandy–Hegsted–Stare *NEJM* literature review that elevated fat and downplayed sucrose while omitting SRF’s role. Kearns, Schmidt, and Glantz’s 2016 *JAMA Internal Medicine* analysis of university-archive industry documents reconstructs that playbook; a 2015 *PLOS Medicine* sibling shows agenda-setting on federal caries research.
No comments yet. Be the first to share your thoughts!